Four new developments are shaping access to GLP-1 medications right now, and they pull in different directions. One study result patients have been waiting on is delayed further. Two new trials are getting underway to answer safety and quality-of-life questions that matter to people already on these drugs. And the FDA has taken a regulatory step that could raise costs for patients who currently rely on compounded versions. Together, these updates affect both what is available and what it costs.
Eli Lilly's trial combining tirzepatide with mibavademab, a new drug aimed at boosting weight loss beyond what tirzepatide achieves alone, has finished enrolling participants. The Phase 2 study closed its enrollment window, but the results are not yet published. For patients hoping this combination might offer a stronger option than tirzepatide by itself, that means more waiting before anyone can say whether it works or how well it is tolerated. Phase 2 results typically take time to compile and review after a trial completes enrollment, so a further delay before publication is expected. Patients considering their options in the meantime should stick with what their doctor has already prescribed rather than adjust treatment based on a trial that has not yet reported.
The RAPID-CKD trial, still listed as not yet recruiting, plans to test whether four guideline-recommended treatments for chronic kidney disease can be started at the same time safely in people with type 2 diabetes and CKD. Right now, doctors typically introduce these medicines one at a time, partly to watch for side effects and partly out of caution about combining them. This Phase 4 study will look at what happens when all four are given together from the start, rather than staggered. If the combination proves safe, it could change how quickly patients with diabetes-related kidney disease get access to full guideline-based treatment. Because the trial has not yet started recruiting, any practical changes for patients are still a long way off.
A separate Phase 4 study, also not yet recruiting, will examine whether a 12-week program of exercise and individualized nutrition counseling can reduce the muscle and bone loss that some patients experience while taking GLP-1 medications for obesity. This is a small, university-run trial, and it focuses specifically on strength, fitness, and daily function rather than weight loss itself. Muscle loss during rapid weight loss has been a concern raised by clinicians and patients, and this study is one attempt to test a structured, non-drug response to it. Because the study has not begun recruiting participants, any findings on whether this approach helps are still some time away. Patients currently on semaglutide who are concerned about muscle loss should raise the topic with their own prescriber rather than wait on this trial's results.
The FDA's proposed rule would remove semaglutide, tirzepatide, and liraglutide from the list of bulk substances that large compounding facilities are permitted to use, closing off the route that many pharmacies have used to produce lower cost versions of these drugs. Compounded versions became widely available in part because of shortages of the brand name products, and many patients turned to them as a more affordable alternative. If this rule takes effect, those large-scale compounding operations would no longer be able to supply patients, and people currently using compounded semaglutide, tirzepatide, or liraglutide may need to return to brand name Ozempic, Wegovy, Mounjaro, or Zepbound at their full list prices. The subtitle notes this could happen within months, not years, which gives patients relatively little time to plan for the change. Anyone currently relying on a compounded version would do well to talk with their pharmacy or prescriber now about what alternatives, insurance coverage, or manufacturer savings programs might be available if the rule goes through.
None of these four developments changes what a patient should do today, but together they suggest two things worth watching. First, the research on GLP-1 medications and related treatments is active, and answers on combination therapies, kidney drug safety, and muscle preservation are coming, just not yet. Second, the regulatory footing under compounded versions of these drugs is shifting, and that shift could affect cost and access sooner than the research does. Patients should keep talking with their prescribers about both fronts, since decisions made in the coming months may depend on which one moves first.
Key details
Patients awaiting Eli Lilly's tirzepatide combo pill will need to wait longer for results.
A 2026 trial will test if four kidney drugs are safe together for diabetic CKD patients.
A small study tests if exercise and nutrition protect muscle for semaglutide users.
The FDA's crackdown on bulk compounding could push patients back toward brand-name prices.
Read this on GLP1Laws: https://glp1laws.com/patient-lens/access-roundup-2026-05-19